Summary of Core Laboratories N.V. (NYSE:CLB) Ratings as of Apr 20, 2018

April 20, 2018 - By Andre Harris

Core Laboratories N.V. (NYSE:CLB) Corporate Logo
Big Money Sentiment decreased to 0.86 in Q4 2017. It has change of 0.21, from 2017Q3’s 1.07. The ratio dropped due to Core Laboratories N.V. positioning: 52 sold and 109 reduced. 54 funds took stakes and 85 increased stakes. Investors holded 49.25 million in 2017Q3 but now own 49.56 million shares or 0.63% more.
Jfs Wealth Advsrs Ltd Liability Corporation accumulated 25 shs. Federated Pa holds 0.01% in Core Laboratories N.V. (NYSE:CLB) or 17,546 shs. Georgia-based Synovus Corp has invested 0.01% in Core Laboratories N.V. (NYSE:CLB). Franklin Res Incorporated has 0.03% invested in Core Laboratories N.V. (NYSE:CLB) for 490,266 shs. Snyder Management Ltd Partnership holds 33,985 shs. Eaton Vance Management, Massachusetts-based fund reported 464,011 shs. Suntrust Banks accumulated 0% or 2,942 shs. Huntington Retail Bank holds 0% of its capital in Core Laboratories N.V. (NYSE:CLB) for 55 shs. Legal & General Gru Plc holds 206,750 shs. Wedgewood Prtn invested 4.1% of its capital in Core Laboratories N.V. (NYSE:CLB). California Pub Employees Retirement Systems invested in 0.01% or 94,646 shs. Apg Asset Nv holds 0.08% or 474,417 shs in its capital. Dillon Associates holds 4,450 shs or 0.18% of its capital. 11,198 were accumulated by Liberty Mutual Gp Asset Mngmt. Biondo Inv Ltd reported 0.99% in Core Laboratories N.V. (NYSE:CLB).

Core Laboratories N.V. (NYSE:CLB) Ratings Coverage

In total 7 analysts cover Core Laboratories (NYSE:CLB). “Buy” rating has 3, “Sell” are 0, while 4 are “Hold”. (NYSE:CLB) has 43% bullish analysts. 9 are the (NYSE:CLB)’s ratings reports on Apr 20, 2018 according to StockzIntelligence Inc. On Wednesday, October 25 the firm has “Buy” rating by ABN Amro given. On Wednesday, October 25 UBS maintained the shares of CLB in report with “Neutral” rating. On Monday, October 23 Piper Jaffray maintained Core Laboratories N.V. (NYSE:CLB) rating. Piper Jaffray has “Hold” rating and $97.0 target. In Thursday, January 11 report Deutsche Bank downgraded the stock to “Hold” rating. On Friday, April 13 the firm earned “Hold” rating by Cowen & Co. On Monday, January 29 the stock has “Buy” rating by RBC Capital Markets. On Tuesday, March 13 Piper Jaffray initiated Core Laboratories N.V. (NYSE:CLB) with “Hold” rating. In Thursday, December 21 report RBC Capital Markets maintained it with “Buy” rating and $110.0 target. Listed here are Core Laboratories N.V. (NYSE:CLB) PTs and latest ratings.

13/04/2018 Broker: Cowen & Co Rating: Hold New Target: $98.0000 Maintain
13/03/2018 Broker: Piper Jaffray Rating: Hold New Target: $96.0 Initiate
29/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $125.0 Maintain
11/01/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Hold Old Target: $109 Downgrade
21/12/2017 Broker: RBC Capital Markets Rating: Buy New Target: $110.0 Maintain
25/10/2017 Broker: ABN Amro Old Rating: Hold New Rating: Buy Upgrade
25/10/2017 Broker: UBS Rating: Neutral Old Target: $110 New Target: $100 Maintain
25/10/2017 Broker: Loop Capital Markets Rating: Buy New Target: $115.0
23/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $97.0 Maintain

CLB is hitting $121.06 during the last trading session, after decreased 0.61%.Currently Core Laboratories N.V. is downtrending after 4.05% change in last April 20, 2017. CLB has also 113,737 shares volume. The stock underperformed the S&P 500 by 15.60%.

Core Laboratories N.V. provides reservoir description, production enhancement, and reservoir management services to the gas and oil industry in the United States, Canada, and internationally.The firm is valued at $5.35 billion. It operates through three divisions: Reservoir Description, Production Enhancement, and Reservoir Management.64.39 is the P/E ratio. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples.

Core Laboratories N.V. (NYSE:CLB) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.